All In Biotech

Drug Trial Radar · NCT07932496

A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.

A Modular, Phase I/II, Open-label, Single-arm, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of CT204V-CD19 × CD20, an In Vivo Lentiviral Vector Gene Therapy Generating Dual Targeting Anti-CD19/CD20 Chimeric Antigen Receptor (CAR)-T Cells in Participants With Relapsed or Refractory B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Oct 15, 2029

Study completion Oct 15, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CT204V-CD19 × CD20, a dual targeting in vivo gene therapy generating anti-CD19/CD20 CAR-T cells in participants with R/R B-cell malignancies.

Conditions

  • Relapsed or Refractory B-Cell Malignancies

Interventions

  • CT204V-CD19 × CD20Drug

    Experimental

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events(AEs)/Serious Adverse Events (SAEs), Phase 1 of the study.Time frame: Up to 15 years
  2. Number of Dose-Limiting Toxicities (DLTs) events during dose escalation, Phase 1 of the study.Time frame: Up to 28 days.
  3. Number of AEs leading to dose reduction, withdrawal, interruption, Phase 1 of the study.Time frame: Up to 1 year.
  4. Number of AEs leading to death, Phase 1 of the study.Time frame: Up to 15 years
  5. Number of AESI (adverse events of special interest), Phase 1 of the study.Time frame: Up to 15 years
  6. Objective Response Rate (Complete Response+Partial Response) per Lugano Classification, Phase 2 of the study.Time frame: Up to 24 months.
  7. Complete Response (CR) rate, Phase 2 of the study.Time frame: Up to 24 months.
  8. Best Overall Response (BOR), Phase 2 of the study.Time frame: Up to 24 months.
  9. Duration of Response (DoR), Phase 2 of the study.Time frame: Up to 24 months.
  10. Duration of Complete Response (DoCR), Phase 2 of the study.Time frame: Up to 24 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.